The one thing that decides whether a telehealth GLP-1 service is worth your money: transparency. Who made the medication, at what price, under whose supervision, and what happens when you have a question at 10pm on a Tuesday. Everything else is marketing.
I dug through pricing pages, pharmacy disclosures, and recurring complaints in weight-loss forums to put this list together. Here is what kept coming up in the threads I read: people care most about price predictability, pharmacy credibility, and how much hand-holding they get from clinicians. This list is organized around those three things.
1. HealthRX
Cash-pay compounded semaglutide starts at $99/month and compounded tirzepatide at $149/month. Those are genuinely low numbers compared to most telehealth options on this list. Medication is dispensed through Manifest Pharmacy in Greer, South Carolina, a 503A/USP-797 compounding facility with lot-tracking from bench to door. The single fact I keep coming back to: they publish the actual pharmacy name, which a surprising number of competitors still refuse to do. Physician review happens in roughly 24 hours, and shipping is free overnight to all 50 states. LegitScript certified (cert 50087439). Compounded meds are not FDA-approved, and HealthRX makes no equivalency claims to branded drugs.
2. Mochi Health
Board-certified obesity-medicine physicians run the clinical side here, which is rarer than it sounds in telehealth. Compounded semaglutide runs around $99/month and tirzepatide around $199/month. The monitoring is heavier than most cash-pay competitors, with regular check-ins built into the model. Good pick if you want clinical weight-loss expertise and not just a quick prescription.
3. FormBlends
FormBlends is worth a slot if purity documentation matters to you. They publish per-vial test results including HPLC purity percentages, mass spec identity confirmation, and endotoxin/sterility data. Not many GLP-1 telehealth brands go that far. Semaglutide runs around $299 per vial and tirzepatide around $349, so the price is higher than HealthRX’s entry pricing. They ship to 47 states, not 50. The other differentiator: FormBlends carries a broad peptide catalog covering recovery, longevity, and cognitive peptides under the same clinician model. If you want GLP-1s plus other peptide therapies from one provider, and you want published lab documentation, this is the pick. Compounded products, not FDA-approved.
4. Hims & Hers
After the Novo Nordisk settlement in March 2026, Hims & Hers exited compounded GLP-1s and shifted to branded medications only. Injectable Wegovy is now around $299/month through their platform, oral semaglutide around $249/month, and Zepbound around $399/month. With insurance plus a savings card, some patients get down to $0 to $25. Good fit if you have insurance and want a name-brand experience.
5. Ro Body
Ro’s prior-authorization team is genuinely useful if you want to go the insurance route for branded GLP-1s. Membership is about $39 for the first month, then $74 to $149/month, with medication costs billed separately. They take insurance for branded meds. The platform is polished and the support is responsive, based on what consistently shows up in user reviews.
6. Found
Around $99/month for the platform, meds billed separately. Found includes coaching alongside the prescription, which appeals to people who want behavioral support layered in. Not the lowest sticker price once you add medication, but the coaching component is real, not just automated messages.
7. PlushCare
PlushCare charges about $19.99/month for membership and focuses on branded medications through insurance. Same-day visits are available. It functions more like a standard telehealth primary care service that happens to prescribe GLP-1s than a dedicated weight-loss program, which suits some people perfectly.
8. Henry Meds
Henry Meds ships compounded medications on a cash-pay basis, with orders typically arriving within 24 to 72 hours of approval. First-month pricing runs roughly $179 to $249. The clinical monitoring is lighter than Mochi, which is fine for people who prefer minimal check-ins and just want the medication moving quickly.
9. Sesame
Sesame works differently from the others. Annual members pay from around $59/month, and medications are priced separately. It is less of a weight-loss program and more of a marketplace for affordable telehealth visits. If you just need a GLP-1 consultation and already know what you want, the pricing can work in your favor.
10. Form Health
Form Health sits at the top of the price range on this list. Around $299/month covers the platform, labs, an MD, and a registered dietitian working together. It is the closest thing on this list to medically supervised weight management as a full service. The price reflects that. Not for everyone, but for patients with complex metabolic history it may be worth the spend.
What to Sort Out Before You Pick a Provider
The FDA sent warning letters to more than 30 compounding-related telehealth firms in early 2026. That does not mean every compounded GLP-1 provider is problematic, but it does mean pharmacy verification matters. Ask any provider: what is the pharmacy name, is it 503A or 503B, and can you see recent COAs. If they cannot answer those questions directly, that tells you something.
Oral orforglipron from Lilly became available through LillyDirect at roughly $149/month around April 2026, which adds another option for people who want an FDA-approved branded oral without a prior-auth fight.
Prices above reflect publicly listed rates at time of writing and can change.
Common Questions
Which providers on this list are actually transparent about where their compounded medication comes from?
HealthRX names its pharmacy outright: Manifest Pharmacy in Greer, South Carolina, a 503A/USP-797 facility. FormBlends publishes per-vial COA data including HPLC purity and sterility results. Most others do not go that far. If a provider will not name the compounding pharmacy when you ask directly, that is a meaningful red flag.
Does it matter whether a compounding pharmacy is 503A or 503B, and how do I tell which one my provider uses?
It matters practically. A 503A pharmacy compounds per individual prescription and is state-regulated. A 503B outsourcing facility operates under federal FDA oversight and can produce larger batches. Neither designation makes the medication FDA-approved. Ask your provider directly, then cross-check the pharmacy name against the FDA’s 503B registered outsourcing facility list.
After Hims & Hers dropped compounded GLP-1s in early 2026, what are the best alternatives for patients who cannot afford branded Wegovy or Zepbound?
HealthRX at $99/month for compounded semaglutide and Mochi at the same price point are the most direct replacements on a cost basis. Henry Meds starts around $179/month. FormBlends costs more per vial but publishes lab documentation that some patients consider worth the premium. All are compounded and not FDA-approved.
How does Form Health at $299/month justify its price compared to a $99/month option like HealthRX or Mochi?
Form Health bundles an MD, a registered dietitian, and lab work into that monthly fee. The medication cost comes on top. For someone with straightforward goals and no complex metabolic history, the premium is hard to justify. For patients managing comorbidities or who have failed other approaches, having a dietitian and physician coordinating together is a genuinely different level of care.
Is LillyDirect orforglipron worth considering over the compounded options on this list?
At roughly $149/month it sits in the same price range as entry-level compounded semaglutide, but it is an FDA-approved branded oral from the actual manufacturer. No injection required. The tradeoff is that orforglipron is newer than semaglutide or tirzepatide, so long-term real-world data is thinner. For injection-averse patients who qualify, it is a legitimate option to weigh against the compounded injectable services here.
Sources
- FDA 503A compounding pharmacy framework, FDA.gov
- SURMOUNT-1 trial (tirzepatide), *New England Journal of Medicine*, 2022
- STEP 1 trial (semaglutide), *New England Journal of Medicine*, 2021
- Novo Nordisk/Hims & Hers settlement reporting, *STAT News* and *Reuters*, March 2026
- LillyDirect orforglipron pricing announcement, Eli Lilly press release, April 2026
- LegitScript certification public database, LegitScript.com
